@ADurbinLab
St. Jude scientists identified a direct role for PARP1 in chromatin remodeling, revealing for the first time how the protein partially disassembles nucleosomes to make damaged DNA accessible for repair. The findings could lead to more targeted PARP1 inhibitors and potentially reduce treatment toxicity. bit.ly/4zRmFDbView quoted post on X
New research published in @JExpMed from @DanaFarber’s @JunQiLab and collaborators reveals that AKT inhibitors synergize with EP300 degraders to suppress osteosarcoma growth in vitro and in vivo. These agents positively combine across cancer cells in a manner dependent on control of protein synthesis.
➡️bit.ly/4z13y9GView quoted post on X
rupress.org Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300 Here, Delahunty et al. identify that EP300 controls the growth of AKT-dysregulated osteosarcoma cells by regulating expression of state-specific genetic de 
